NR3C1 and attention deficit-hyperactivity disorder: After DEX intervention, the level of 5-HT increased with a decrease in 5-HT1AR and ameliorated attention deficit and hyperactive behaviors, suggesting that the GR agonist or 5-HT1AR inhibitor may serve as a potential target for the treatment of ADHD.